TRPC6 Knockout Alleviates Renal Fibrosis through PI3K/AKT/GSK3B Pathway

Abstract

Objective

Renal fibrosis is the ultimate pathway of various forms of acute and chronic kidney damage. Notably, the knockout of transient receptor potential channel 6 (TRPC6) has shown promise in alleviating renal fibrosis. However, the regulatory impact of TRPC6 on renal fibrosis remains unclear.

Methods

In vivo, TRPC6 knockout (TRPC6^−/−) mice and age-matched 129 SvEv (WT) mice underwent unilateral renal ischemia-reperfusion (uIR) injury surgery on the left renal pedicle or sham operation. Kidneys and serum were collected on days 7, 14, 21, and 28 after euthanasia. In vitro, primary tubular epithelial cells (PTECs) were isolated from TRPC6^−/− and WT mice, followed by treatment with transforming growth factor β1 (TGFβ1) for 72 h. The anti-fibrotic effect of TRPC6^−/− and the underlying mechanisms were assessed through hematoxylin-eosin staining, Masson staining, immunostaining, qRT-PCR, and Western blotting.

Results

Increased TRPC6 expression was observed in uIR mice and PTECs treated with TGFβ1. TRPC6^−/− alleviated renal fibrosis by reducing the expression of fibrotic markers (Col-1, α-SMA, and vimentin), as well as decreasing the apoptosis and inflammation of PTECs during fibrotic progression both in vivo and in vitro. Additionally, we found that the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/glycogen synthase kinase 3 beta (GSK3β) signaling pathway, a pivotal player in renal fibrosis, was down-regulated following TRPC6 deletion.

Conclusion

These results suggest that the ablation of TRPC6 may mitigate renal fibrosis by inhibiting the apoptosis and inflammation of PTECs through down-regulation of the PI3K/AKT/GSK3β pathway. Targeting TRPC6 could be a novel therapeutic strategy for preventing chronic kidney disease.

Keywords

transient receptor potential channel 6 / ischemia-reperfusion injury / renal fibrosis / renal tubular epithelial cells

References

[1] Ruiz-OrtegaM, Rayego-MateosS, LamasS, et al.. Targeting the progression of chronic kidney disease. Nat Rev Nephrol, 2020, 16(5): 269-88

[2] DjudjajS, BoorP. Cellular and molecular mechanisms of kidney fibrosis. Mol Aspects Med, 2019, 65: 16-36

[3] YamashitaN, KramannR. Mechanisms of kidney fibrosis and routes towards therapy. Trends Endocrinol Metab, 2024, 35(1): 31-48

[4] BasileDP, BonventreJV, MehtaR, et al.. Progression after AKI: Understanding Maladaptive Repair Processes to Predict and Identify Therapeutic Treatments. J Am Soc Nephrol, 2016, 27(3): 687-697

[5] HumphreysBD. Mechanisms of Renal Fibrosis. Annu Rev Physiol, 2018, 80: 309-326

[6] ZukA, BonventreJV. Acute Kidney Injury. Annu Rev Med, 2016, 67: 293-307

[7] LiuBC, TangTT, LvLL, et al.. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int, 2018, 93(3): 568-579

[8] HouX, XiaoH, ZhangY, et al.. Transient receptor potential channel 6 knockdown prevents apoptosis of renal tubular epithelial cells upon oxidative stress via autophagy activation. Cell Death Dis, 2018, 9(10): 1015

[9] ZhangY, YinN, SunA, et al.. Transient Receptor Potential Channel 6 Knockout Ameliorates Kidney Fibrosis by Inhibition of Epithelial-Mesenchymal Transition. Front Cell Dev Biol, 2020, 8: 602703

[10] DryerSE, RoshanravanH, KimEY. TRPC channels: Regulation, dysregulation and contributions to chronic kidney disease. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6): 1041-1066

[11] DietrichA, ChubanovV, GudermannT. Renal TRPathies. J Am Soc Nephrol, 2010, 21(5): 736-744

[12] HallG, WangL, SpurneyRF. TRPC Channels in Proteinuric Kidney Diseases. Cells, 2019, 9(1): 44

[13] HofstraJM, LainezS, van KuijkWH, et al.. New TRPC6 gain-of-function mutation in a non-consanguineous Dutch family with late-onset focal segmental glomerulosclerosis. Nephrol Dial Transplant, 2013, 28(7): 1830-1838

[14] WinnMP, ConlonPJ, LynnKL, et al.. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science, 2005, 308(5729): 1801-1804

[15] LiuB, HeX, LiS, et al.. Deletion of diacylglycerol-responsive TRPC genes attenuates diabetic nephropathy by inhibiting activation of the TGFbeta1 signaling pathway. Am J Transl Res, 2017, 9(12): 5619-5630

[16] ZhangB, ChenZY, JiangZ, et al.. Nephroprotective Effects of Cardamonin on Renal Ischemia Reperfusion Injury/UUO-Induced Renal Fibrosis. J Agric Food Chem, 2023, 71(36): 13284-13303

[17] BlackLM, LeverJM, TraylorAM, et al.. Divergent effects of AKI to CKD models on inflammation and fibrosis. Am J Physiol Renal Physiol, 2018, 315(4): F1107-F1118

[18] ShuS, ZhuJ, LiuZ, et al.. Endoplasmic reticulum stress is activated in post-ischemic kidneys to promote chronic kidney disease. EBioMedicine, 2018, 37: 269-280

[19] WuYL, XieJ, AnSW, et al.. Inhibition of TRPC6 channels ameliorates renal fibrosis and contributes to renal protection by soluble klotho. Kidney Int, 2017, 91(4): 830-841

[20] IlatovskayaDV, BlassG, PalyginO, et al.. A NOX4/TRPC6 Pathway in Podocyte Calcium Regulation and Renal Damage in Diabetic Kidney Disease. J Am Soc Nephrol, 2018, 29(7): 1917-1927

[21] LinBL, MateraD, DoernerJF, et al.. In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease. Proc Natl Acad Sci USA, 2019, 116(20): 10156-10161

[22] SpiresD, IlatovskayaDV, LevchenkoV, et al.. Protective role of Trpc6 knockout in the progression of diabetic kidney disease. Am J Physiol Renal Physiol, 2018, 315(4): F1091-F1097

[23] KangHM, AhnSH, ChoiP, et al.. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med, 2015, 21(1): 37-46

[24] ZhouY, ZhouB, PacheL, et al.. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun, 2019, 10(1): 1523

[25] Skrypnyk NI, Harris RC, de Caestecker MP. Ischemia-reperfusion model of acute kidney injury and post injury fibrosis in mice. J Vis Exp, 2013(78):50495

[26] ZhouT, LuoM, CaiW, et al.. Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ. EBioMedicine, 2018, 31: 217-225

[27] HouX, HuangM, ZengX, et al.. The Role of TRPC6 in Renal Ischemia/Reperfusion and Cellular Hypoxia/Reoxygenation Injuries. Front Mol Biosci, 2021, 8: 698975

[28] LiF, SunA, ChengG, et al.. Compound C Protects Against Cisplatin-Induced Nephrotoxicity Through Pleiotropic Effects. Front Physiol, 2020, 11: 614244

[29] YuM, PengZ, QinM, et al.. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation. Mol Cell, 2021, 81(6): 1216-1230.e9

[30] FuY, TangC, CaiJ, et al.. Rodent models of AKI-CKD transition. Am J Physiol Renal Physiol, 2018, 315(4): F1098-F1106

[31] HeL, WeiQ, LiuJ, et al.. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int, 2017, 92(5): 1071-1083

[32] VenkatachalamMA, WeinbergJM, KrizW, et al.. Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression. J Am Soc Nephrol, 2015, 26(8): 1765-1776

[33] KrizW, LeHirM. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int, 2005, 67(2): 404-419

[34] ZhaoX, KwanJYY, YipK, et al.. Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov, 2020, 19(1): 57-75

[35] KimIY, SongSH, SeongEY, et al.. Akt1 is involved in renal fibrosis and tubular apoptosis in a murine model of acute kidney injury-to-chronic kidney disease transition. Exp Cell Res, 2023, 424(2): 113509

[36] YuX, XiaoQ, YuX, et al.. A network pharmacology-based study on the mechanism of astragaloside IV alleviating renal fibrosis through the AKT1/GSK-3β pathway. J Ethnopharmacol, 2022, 297: 115535

[37] LindemannO, UmlaufD, FrankS, et al.. TRPC6 regulates CXCR2-mediated chemotaxis of murine neutrophils. J Immunol, 2013, 190(11): 5496-5505

[38] AiZ, WangM, ZhouY, et al.. Deciphering the pharmacological mechanisms of Rostellularia procumbens (L) Nees. Extract alleviates adriamycin-induced nephropathy in vivo and in vitro. Phytomedicine, 2023, 113: 154736

[39] MaR, ChaudhariS, LiW. Canonical Transient Receptor Potential 6 Channel: A New Target of Reactive Oxygen Species in Renal Physiology and Pathology. Antioxid Redox Signal, 2016, 25(13): 732-748

[40] ReiserJ, PoluKR, MöllerCC, et al.. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet, 2005, 37(7): 739-744

[41] GuLF, GeHT, ZhaoL, et al.. Huangkui Capsule Ameliorates Renal Fibrosis in a Unilateral Ureteral Obstruction Mouse Model Through TRPC6 Dependent Signaling Pathways. Front Pharmacol, 2020, 11: 996

[42] KimEY, DryerSE. Effects of TRPC6 Inactivation on Glomerulosclerosis and Renal Fibrosis in Aging Rats. Cells, 2021, 10(4): 856

[43] SantínS, ArsE, RossettiS, et al.. TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant, 2009, 24(10): 3089-3096

[44] GiganteM, CaridiG, MontemurnoE, et al.. TRPC6 mutations in children with steroid-resistant nephrotic syndrome and atypical phenotype. Clin J Am Soc Nephrol, 2011, 6(7): 1626-1634

[45] ShenB, HeY, ZhouS, et al.. TRPC6 May Protect Renal Ischemia-Reperfusion Injury Through Inhibiting Necroptosis of Renal Tubular Epithelial Cells. Med Sci Monit, 2016, 22: 633-641

[46] Ghaffari-NasabA, GhiasiF, KeyhanmaneshR, et al.. Bone marrow-derived c-kit positive stem cell administration protects against diabetes-induced nephropathy in a rat model by reversing PI3K/AKT/GSK-3β pathway and inhibiting cell apoptosis. Mol Cell Biochem, 2024, 479(3): 603-615

[47] ZhangB, ZengM, LiB, et al.. Arbutin attenuates LPS-induced acute kidney injury by inhibiting inflammation and apoptosis via the PI3K/Akt/Nrf2 pathway. Phytomedicine, 2021, 82: 153466

[48] KattlaJJ, CarewRM, HeljicM, et al.. Protein kinase B/Akt activity is involved in renal TGF-beta1-driven epithelial-mesenchymal transition in vitro and in vivo. Am J Physiol Renal Physiol, 2008, 295(1): F215-F225